Glucarpidase

Summary

Glucarpidase (CHEMBL1863515) is an approved enzyme (ATC V03AF09); indicated across 7 conditions including acute lymphoblastic leukemia and osteosarcoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: V03AF09
• Indications: 7 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1863515
Name	Glucarpidase
Type	Enzyme
Max phase	4
ATC	V03AF09

Also known as: .gamma.-glu-x carboxypeptidase, Carboxypeptidase g2, Folate hydrolase g2, Glucarpidasa, Glucarpidase, Voraxaze, GLUCARPIDASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
acute lymphoblastic leukemia	3	MONDO:0004967	EFO:0000220
osteosarcoma	2	MONDO:0009807	EFO:0000637
neoplasm	2	MONDO:0005070	EFO:0000616
lymphoma	2	MONDO:0005062	EFO:0000574
hematopoietic and lymphoid system neoplasm	1	MONDO:0002334	MONDO:0044881

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE2	5
Not specified	3
PHASE1/PHASE2	2
PHASE1	2
EARLY_PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01305655	PHASE3	COMPLETED	Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
NCT00219791	PHASE2	COMPLETED	Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
NCT00424645	PHASE1/PHASE2	TERMINATED	Voraxaze for Delayed Methotrexate Clearance
NCT00634322	PHASE2	TERMINATED	High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
NCT00727831	PHASE1/PHASE2	COMPLETED	Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT02022358	PHASE2	TERMINATED	Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
NCT04668768	PHASE2	SUSPENDED	HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
NCT05022797	PHASE2	TERMINATED	Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
NCT00634504	PHASE1	COMPLETED	Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze
NCT05135858	PHASE1	UNKNOWN	Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma
NCT03684980	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
NCT03960177	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
NCT00018967	Not specified	COMPLETED	Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
NCT00481559	Not specified	APPROVED_FOR_MARKETING	Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
NCT05899751	Not specified	UNKNOWN	Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).